Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

BACKGROUND: The best strategy for maintaining clinical remission in patients with axial spondyloarthritis (axSpA) has not been defined. C-OPTIMISE compared dose continuation, reduction and withdrawal of the tumour necrosis factor inhibitor certolizumab pegol (CZP) following achievement of sustained...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Rheum Dis
Autors principals: Landewé, Robert BM, van der Heijde, Désirée, Dougados, Maxime, Baraliakos, Xenofon, Van den Bosch, Filip E, Gaffney, Karl, Bauer, Lars, Hoepken, Bengt, Davies, Owen R, de Peyrecave, Natasha, Thomas, Karen, Gensler, Lianne
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Spondyloarthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307216/
https://ncbi.nlm.nih.gov/pubmed/32381562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2019-216839
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars